Literature DB >> 19231325

Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).

Leonard Schwartz1, Kevin E Kip, Edwin Alderman, Jiang Lu, Eric R Bates, Vankeepuram Srinivas, Richard G Bach, Lisa D Mighton, Frederick Feit, Spencer King, Robert L Frye.   

Abstract

This report describes the baseline angiographic findings in the Bypass Angioplasty Revascularization Investigation (BARI) 2 Diabetes (BARI 2D) trial, a randomized study that was initiated after the original BARI trial (BARI 1). Unlike BARI 1, which compared coronary artery bypass graft surgery with coronary angioplasty (percutaneous coronary intervention) in patients with and without diabetes, BARI 2D is investigating early versus deferred revascularization as needed in selected patients with type 2 diabetes mellitus and significant stable coronary artery disease (CAD). This analysis included 1,773 patients without previous procedures. The intended mode of revascularization, percutaneous coronary intervention or coronary artery bypass graft surgery, was specified before randomization. Angiographic findings in those randomized to revascularization versus medical treatment were similar. Overall, the mean number of lesions >or=20% diameter stenosis was 4.6 +/- 2.3, and the myocardial jeopardy index was 46 +/- 24%. Patients selected for the coronary artery bypass graft stratum had a higher mean number of lesions >or=20% diameter stenosis (5.7 vs 4.0, p <0.0001) and a higher myocardial jeopardy index (61% vs 38%, p <0.0001) than those selected for the percutaneous coronary intervention stratum. Female gender, black race, and higher body mass index were associated with less extensive CAD, whereas a history of hypertension, age at entry, low-density lipoprotein cholesterol, and ankle-brachial index <or=0.9 were associated with more extensive CAD. In conclusion, BARI 2D patients, who by design have mild or no symptoms, demonstrate considerable variation in the extent of CAD and amount of jeopardized myocardium. Coronary arteriographic findings are consistent with the intent of the design of BARI 2D. Certain baseline and clinical features were associated with the extent of disease and myocardial jeopardy.

Entities:  

Mesh:

Year:  2009        PMID: 19231325     DOI: 10.1016/j.amjcard.2008.11.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Binita Shah; Vankeepuram S Srinivas; Jiang Lu; Maria M Brooks; Eric R Bates; Zoran S Nedeljkovic; Jorge Escobedo; Gladwin S Das; John J Lopez; Frederick Feit
Journal:  Am Heart J       Date:  2013-08-06       Impact factor: 4.749

2.  Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial.

Authors:  Sharon Cresci; Jun Wu; Michael A Province; John A Spertus; Michael Steffes; Janet B McGill; Edwin L Alderman; Maria Mori Brooks; Sheryl F Kelsey; Robert L Frye; Richard G Bach
Journal:  Circulation       Date:  2011-09-12       Impact factor: 29.690

3.  Appropriate revascularization in stable angina: lessons from the BARI 2D trial.

Authors:  Ronald J Krone; Andrew D Althouse; Jacqueline Tamis-Holland; Lakshmi Venkitachalam; Arturo Campos; Alan Forker; Alice K Jacobs; Salvador Ocampo; George Steiner; Francisco Fuentes; Ivan R Pena Sing; Maria Mori Brooks
Journal:  Can J Cardiol       Date:  2014-08-20       Impact factor: 5.223

4.  The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry.

Authors:  Sameer Bansilal; Michael E Farkouh; Whady Hueb; May Ogdie; George Dangas; Alexandra J Lansky; David J Cohen; Elizabeth A Magnuson; Krishnan Ramanathan; Jean-Francois Tanguay; Victoria Muratov; Lynn A Sleeper; Michael Domanski; Michel E Bertrand; Valentin Fuster
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

5.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Authors:  Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

6.  Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Mark A Hlatky; Derek B Boothroyd; Kathryn A Melsop; Laurence Kennedy; Charanjit Rihal; William J Rogers; Lakshmi Venkitachalam; Maria M Brooks
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

7.  Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Maria Mori Brooks; Bernard R Chaitman; Richard W Nesto; Regina M Hardison; Frederick Feit; Bernard J Gersh; Ronald J Krone; Edward Y Sako; William J Rogers; Alan J Garber; Spencer B King; Charles J Davidson; Fumiaki Ikeno; Robert L Frye
Journal:  Circulation       Date:  2012-09-24       Impact factor: 29.690

8.  Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial.

Authors:  Derek S Chew; Patricia A Cowper; Hussein Al-Khalidi; Kevin J Anstrom; Melanie R Daniels; Linda Davidson-Ray; Yanhong Li; Robert E Michler; Julio A Panza; Ileana L Piña; Jean L Rouleau; Eric J Velazquez; Daniel B Mark
Journal:  Circulation       Date:  2022-01-19       Impact factor: 29.690

9.  Choosing a revascularization strategy in patients with diabetes and stable coronary artery disease: a complex decision.

Authors:  Antonio Sergio Rocha; Paulo Dutra; Andrea De Lorenzo
Journal:  Curr Cardiol Rev       Date:  2010-11

Review 10.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.